News

April 15, 2020 — Crinetics has raised $100 million via public offering of 7.2 million shares of its stock to fund research for the treatment of rare diseases such as acromegaly, Cushing's disease, congenital hyperinsulinism, and congenital adrenal hyperplasia. Read the full article on Global Genes - Allies in Rare Disease.

Crinetics has completed a $63.5 million Series B financing to continue development of its lead product for acromegaly and other new therapeutics targeting rare endocrine disorders.

November 2, 2015 — After spending the past six years scavenging for lab equipment and operating on a shoestring, San Diego’s Crinetics Pharmaceuticals has finally landed its first round of institutional funding.